secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001823239-24-000105
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai reports Q3 loss of $176M on $154.2M goodwill impairment; acquires Officinae Bio DNA/RNA business
--------------------------------------------------------------------------------

- Q3 revenue $65.2M (down 2.5% YoY); net loss $(176.0)M includes $154.2M goodwill impairment.
- Adjusted EBITDA $12.7M vs $11.9M in Q3 2023.
- FY2024 revenue guidance lowered to $255-265M (from prior outlook).
- Agreed to acquire Officinae Bio's DNA/RNA business (AI-driven platform); close expected early 2025.
- Nucleic Acid Production revenue $49.9M (down 2.5% YoY); Biologics Safety Testing $15.3M (down 2.5%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323924000105/0001823239-24-000105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323924000105/mrvi-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001823239-24-000105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer